Research Paper Volume 13, Issue 2 pp 2780—2802

Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer

class="figure-viewer-img"

Figure 10. Variations in the mutation landscape and molecular features of the high and low-risk UBCs in TCGA-BLCA cohort. (A) Mutation landscapes of UBC samples in the low- and high-risk groups. (B) Association between the 10-genes risk model and molecular subtypes of UBC patients in the TCGA-BLCA dataset. (C, D) Normalized PD1 and PD-L1 gene expression profile in the low- and high-risk groups.